MiNK Therapeutics (INKT) Total Current Liabilities (2020 - 2026)

MiNK Therapeutics has reported Total Current Liabilities for 7 years, with the latest figure at $7.3 million in Q1 2026.

• Quarterly Total Current Liabilities fell 39.87% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (down 39.87% YoY) and the FY2025 annual result came in at $13.0 million, up 87.24% from the prior year.
• Total Current Liabilities eased to $7.3 million in Q1 2026 per INKT's latest filing, from $13.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $18.8 million in Q1 2022 and troughed at $7.0 million in Q4 2024.
• A 5-year average of $12.2 million and a median of $11.5 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities plunged 77.1% in 2022, then jumped 87.24% in 2025.
• Over 5 years, Total Current Liabilities stood at $12.7 million in 2022, then decreased by 10.1% to $11.4 million in 2023, then tumbled by 38.96% to $7.0 million in 2024, then surged by 87.24% to $13.0 million in 2025, then sank by 44.08% to $7.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $7.3 million, $13.0 million, and $13.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.